TMDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TransMedics Group Inc (TMDX) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The company's strong financial performance, positive analyst sentiment, and robust growth outlook outweigh the minor pre-market dip and neutral trading sentiment. The stock's long-term potential aligns well with the investor's goals.
The stock is in a neutral technical position with RSI at 51.257, indicating no overbought or oversold conditions. The MACD histogram is slightly negative (-0.0136), but contracting, suggesting potential stabilization. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 135.122, with key support at 128.628 and resistance at 141.616.
Strong Q4 2025 financials with 32% YoY revenue growth, 1436.87% YoY net income growth, and 1252.63% YoY EPS growth.
Positive analyst sentiment with multiple price target increases and ratings of Buy or Outperform.
Release of a $103.3 million U.S. tax valuation allowance, significantly improving financial position.
Continued dominance in the organ transplant market, with no significant competition from Bridge to Life's VitaSmart.
Gross margin dropped slightly to 58.11%, down 1.86% YoY.
Pre-market price is down 1.51%, reflecting minor short-term weakness.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
TransMedics delivered exceptional Q4 2025 results, with revenue of $160.8 million (32% YoY growth), net income of $105.38 million (1436.87% YoY growth), and EPS of $2.57 (1252.63% YoY growth). However, gross margin declined slightly to 58.11%. The company projects 2026 revenue between $727 million and $757 million, indicating strong growth potential.
Analysts are overwhelmingly positive on TMDX, with multiple price target increases ranging from $149 to $175. Analysts highlight strong Q4 results, robust guidance, and continued market dominance in organ transplantation. Piper Sandler, Oppenheimer, and Evercore ISI all maintain bullish ratings, citing growth in liver, heart, and lung segments, as well as European expansion opportunities.
